Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti)
Aspergillosis is a fungal infection caused mainly by Aspergillus fumigatus that often results in respiratory disease in birds. Aspergillosis is a major cause of morbidity and mortality in captive-bred penguin species. Currently, there is no registered vaccine to prevent aspergillosis. Recent researc...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.897223/full |
| _version_ | 1811258283473764352 |
|---|---|
| author | Milan Thorel Lourdes Mateos-Hernandez Baptiste Mulot Mouna Naila Azzouni Adnan Hodžić Hugues Gaillot Yannick Ruel Guillaume Desoubeaux Guillaume Desoubeaux Jean-Baptiste Delaye Dasiel Obregon Alejandra Wu-Chuang José de la Fuente José de la Fuente Luis G. Bermúdez-Humarán Veronica Risco-Castillo Antoine Leclerc Alejandro Cabezas-Cruz |
| author_facet | Milan Thorel Lourdes Mateos-Hernandez Baptiste Mulot Mouna Naila Azzouni Adnan Hodžić Hugues Gaillot Yannick Ruel Guillaume Desoubeaux Guillaume Desoubeaux Jean-Baptiste Delaye Dasiel Obregon Alejandra Wu-Chuang José de la Fuente José de la Fuente Luis G. Bermúdez-Humarán Veronica Risco-Castillo Antoine Leclerc Alejandro Cabezas-Cruz |
| author_sort | Milan Thorel |
| collection | DOAJ |
| description | Aspergillosis is a fungal infection caused mainly by Aspergillus fumigatus that often results in respiratory disease in birds. Aspergillosis is a major cause of morbidity and mortality in captive-bred penguin species. Currently, there is no registered vaccine to prevent aspergillosis. Recent research demonstrated that oral administration of gram-negative bacteria expressing high levels of galactose-α-1,3-galactose (α-Gal) modulates anti-α-Gal immunity and protects turkeys from clinical aspergillosis caused by experimental A. fumigatus infection. The role of anti-α-Gal immunity in penguins has not been studied. Here, we tested the distribution of α-1,3-galactosyltransferase (α1,3GT) genes in the fecal microbiome of Humboldt penguins (Spheniscus humboldti). The occurrence of natural anti-α-Gal antibodies (Abs) in sera and eggs of healthy Humboldt penguins was also assessed. A trial was then conducted to test whether oral administration of Escherichia coli Nissle, expressing high α-Gal levels, modulates anti-α-Gal immunity in a colony of Humboldt penguins. Animals in the vaccination and placebo groups were evaluated before the trial and followed for one year for aspergillosis detection using a diagnostic panel including computed tomography scans, capillary zone electrophoresis, 3-hydroxybutyrate levels, and anti-A. fumigatus Abs. Anti-α-Gal Abs were detected in sera (IgM and IgY) and eggs (IgY) of healthy penguins. Microbiota analysis and functional predictions revealed the presence of α1,3GT genes in the microbiota of Humboldt penguins and other penguin species. A strong decrease in anti-α-Gal IgM levels was observed in all animals in the placebo group three months after vaccination protocol. This decrease was not observed in E. coli Nissle-treated penguins. After the vaccination protocol, we found a positive correlation between anti-E. coli IgY and anti-α-Gal IgY in the E. coli Nissle group, suggesting a correlation between the presence of the bacteria and these Abs. During the study period, three penguins exhibited respiratory signs consistent with aspergillosis. Two were from the placebo group whose symptoms resolved with specific treatments, while a single vaccinated individual developed fatal respiratory aspergillosis eight months after the trial. We conclude that E. coli Nissle represents a safe potential probiotic with a protective effect against aspergillosis in Humboldt penguins that deserves to be further explored for therapeutic uses in these animals. |
| first_indexed | 2024-04-12T18:11:49Z |
| format | Article |
| id | doaj.art-24891408bd1c40468688b34e08b61ca1 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T18:11:49Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-24891408bd1c40468688b34e08b61ca12022-12-22T03:21:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-05-011310.3389/fimmu.2022.897223897223Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti)Milan Thorel0Lourdes Mateos-Hernandez1Baptiste Mulot2Mouna Naila Azzouni3Adnan Hodžić4Hugues Gaillot5Yannick Ruel6Guillaume Desoubeaux7Guillaume Desoubeaux8Jean-Baptiste Delaye9Dasiel Obregon10Alejandra Wu-Chuang11José de la Fuente12José de la Fuente13Luis G. Bermúdez-Humarán14Veronica Risco-Castillo15Antoine Leclerc16Alejandro Cabezas-Cruz17ZooParc de Beauval and Beauval Nature, Saint-Aignan-sur-Cher, FranceAnses, INRAE, Ecole Nationale Vétérinaire d’Alfort, UMR BIPAR, Laboratoire de Santé Animale, Maisons-Alfort, FranceZooParc de Beauval and Beauval Nature, Saint-Aignan-sur-Cher, FranceAnses, INRAE, Ecole Nationale Vétérinaire d’Alfort, UMR BIPAR, Laboratoire de Santé Animale, Maisons-Alfort, FranceDepartment of Pathobiology, Institute of Parasitology, University of Veterinary Medicine Vienna, Vienna, AustriaADVETIA Veterinary Hospital Center, Vélizy-Villacoublay, FranceADVETIA Veterinary Hospital Center, Vélizy-Villacoublay, FranceCHU de Tours, Service de Parasitologie, Mycologie, Médecine Tropicale, Tours, FranceUniversité de Tours, Inserm U1100 – Centre d’Etude des Pathologies Respiratoires, Faculté de Médecine, Tours, FranceCHU de Tours, Pôle de Biologie médicale, Laboratoire de Médecine Nucléaire In Vitro – Centre Régional de Dépistage Néonatal, Tours, FranceSchool of Environmental Sciences, University of Guelph, Guelph, ON, CanadaAnses, INRAE, Ecole Nationale Vétérinaire d’Alfort, UMR BIPAR, Laboratoire de Santé Animale, Maisons-Alfort, FranceSaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ciudad Real, Spain0Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK, United States1Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France2EA 7380 Dynamyc, UPEC, USC, ANSES, Ecole nationale vétérinaire d’Alfort, Université Paris-Est, Maisons-Alfort, FranceZooParc de Beauval and Beauval Nature, Saint-Aignan-sur-Cher, FranceAnses, INRAE, Ecole Nationale Vétérinaire d’Alfort, UMR BIPAR, Laboratoire de Santé Animale, Maisons-Alfort, FranceAspergillosis is a fungal infection caused mainly by Aspergillus fumigatus that often results in respiratory disease in birds. Aspergillosis is a major cause of morbidity and mortality in captive-bred penguin species. Currently, there is no registered vaccine to prevent aspergillosis. Recent research demonstrated that oral administration of gram-negative bacteria expressing high levels of galactose-α-1,3-galactose (α-Gal) modulates anti-α-Gal immunity and protects turkeys from clinical aspergillosis caused by experimental A. fumigatus infection. The role of anti-α-Gal immunity in penguins has not been studied. Here, we tested the distribution of α-1,3-galactosyltransferase (α1,3GT) genes in the fecal microbiome of Humboldt penguins (Spheniscus humboldti). The occurrence of natural anti-α-Gal antibodies (Abs) in sera and eggs of healthy Humboldt penguins was also assessed. A trial was then conducted to test whether oral administration of Escherichia coli Nissle, expressing high α-Gal levels, modulates anti-α-Gal immunity in a colony of Humboldt penguins. Animals in the vaccination and placebo groups were evaluated before the trial and followed for one year for aspergillosis detection using a diagnostic panel including computed tomography scans, capillary zone electrophoresis, 3-hydroxybutyrate levels, and anti-A. fumigatus Abs. Anti-α-Gal Abs were detected in sera (IgM and IgY) and eggs (IgY) of healthy penguins. Microbiota analysis and functional predictions revealed the presence of α1,3GT genes in the microbiota of Humboldt penguins and other penguin species. A strong decrease in anti-α-Gal IgM levels was observed in all animals in the placebo group three months after vaccination protocol. This decrease was not observed in E. coli Nissle-treated penguins. After the vaccination protocol, we found a positive correlation between anti-E. coli IgY and anti-α-Gal IgY in the E. coli Nissle group, suggesting a correlation between the presence of the bacteria and these Abs. During the study period, three penguins exhibited respiratory signs consistent with aspergillosis. Two were from the placebo group whose symptoms resolved with specific treatments, while a single vaccinated individual developed fatal respiratory aspergillosis eight months after the trial. We conclude that E. coli Nissle represents a safe potential probiotic with a protective effect against aspergillosis in Humboldt penguins that deserves to be further explored for therapeutic uses in these animals.https://www.frontiersin.org/articles/10.3389/fimmu.2022.897223/fullα-Gal VaccineaspergillosisAspergillus fumigatusprobioticsE. coli Nissle 1917penguins |
| spellingShingle | Milan Thorel Lourdes Mateos-Hernandez Baptiste Mulot Mouna Naila Azzouni Adnan Hodžić Hugues Gaillot Yannick Ruel Guillaume Desoubeaux Guillaume Desoubeaux Jean-Baptiste Delaye Dasiel Obregon Alejandra Wu-Chuang José de la Fuente José de la Fuente Luis G. Bermúdez-Humarán Veronica Risco-Castillo Antoine Leclerc Alejandro Cabezas-Cruz Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti) Frontiers in Immunology α-Gal Vaccine aspergillosis Aspergillus fumigatus probiotics E. coli Nissle 1917 penguins |
| title | Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti) |
| title_full | Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti) |
| title_fullStr | Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti) |
| title_full_unstemmed | Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti) |
| title_short | Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti) |
| title_sort | assessment of the safety and efficacy of an oral probiotic based vaccine against aspergillus infection in captive bred humboldt penguins spheniscus humboldti |
| topic | α-Gal Vaccine aspergillosis Aspergillus fumigatus probiotics E. coli Nissle 1917 penguins |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.897223/full |
| work_keys_str_mv | AT milanthorel assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT lourdesmateoshernandez assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT baptistemulot assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT mounanailaazzouni assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT adnanhodzic assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT huguesgaillot assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT yannickruel assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT guillaumedesoubeaux assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT guillaumedesoubeaux assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT jeanbaptistedelaye assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT dasielobregon assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT alejandrawuchuang assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT josedelafuente assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT josedelafuente assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT luisgbermudezhumaran assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT veronicariscocastillo assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT antoineleclerc assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti AT alejandrocabezascruz assessmentofthesafetyandefficacyofanoralprobioticbasedvaccineagainstaspergillusinfectionincaptivebredhumboldtpenguinsspheniscushumboldti |